Last reviewed 2026-04-23 · How we verify

Supemtek®

Supemtek is a small molecule drug that targets the dopamine D2 receptor.

Supemtek is a small molecule drug that targets the dopamine D2 receptor. Used for Treatment of schizophrenia.

At a glance

Mechanism of action

Supemtek works by selectively blocking the dopamine D2 receptor, which is involved in the regulation of movement and other functions. This blockade leads to an increase in the activity of dopamine in the brain, which helps to alleviate symptoms of schizophrenia and other related disorders.

Approved indications

• Treatment of schizophrenia

Common side effects

• Akathisia
• Dystonia
• Parkinsonism
• Tardive dyskinesia
• Somnolence
• Dizziness
• Headache
• Nausea
• Vomiting
• Diarrhea

Key clinical trials

• A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
• Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
• Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Supemtek® CI brief — competitive landscape report
• Supemtek® updates RSS · CI watch RSS
• Assistance Publique - Hôpitaux de Paris portfolio CI